AbbVie Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition brings a portfolio of differentiated, long-acting antibody assets to strengthen the immunology and respiratory pipelines, with the lead asset targeting atopic dermatitis and potential mega blockbuster sales. The $10.9B all-cash deal is expected to be accretive by 2032, leveraging clinical and commercial synergies for long-term growth.
-
Management outlined a strategy focused on four main growth pillars—immunology, oncology, neuroscience, and aesthetics—with obesity as an emerging area. Strong pipeline progress was highlighted in oncology and immunology, while robust financial performance and active business development support long-term growth.
-
Management projects strong revenue and margin growth through 2031, driven by core products, diversified pipeline, and strategic M&A. Key innovations include new obesity assets, combination therapies in IBD, and advances in CAR T and psychedelics.
-
Record revenues and strong sales growth fueled increased R&D and strategic investments. Shareholders approved director elections, auditor ratification, and executive compensation, but rejected proposals to eliminate supermajority voting and require an independent board chair.
-
First quarter 2026 results surpassed expectations with 12.4% revenue growth and strong performance in immunology and neuroscience. Full-year guidance was raised, pipeline progress continued, and significant investments in manufacturing and R&D were announced.
-
Management projects robust growth through the decade, driven by strong performance in immunology and neuroscience, with SKYRIZI and RINVOQ leading. Multiple pivotal readouts are expected this year across immunology, oncology, and neuroscience, while disciplined R&D and business development support long-term growth.
-
Management highlighted robust R&D progress, including high-efficacy immunology assets, innovative trial strategies, and a strong pipeline in neuroscience and oncology. Financial outlook projects high single-digit growth through 2029, with continued investment and new launches expected to drive long-term expansion.
-
Lutikizumab and RINVOQ are advancing in HS with strong phase II data and a focus on clinical differentiation. In IBD, combination strategies with SKYRIZI, TL1A, and novel mechanisms like TREM1 are prioritized, while next-generation oral and B-cell therapies expand the pipeline.
-
Operational momentum is strong, with high single-digit sales growth targeted through the decade and robust R&D investment. Immunology and neuroscience franchises are driving growth, while oncology and obesity represent key expansion areas. Multiple pipeline readouts and innovation in aesthetics and combination therapies are expected in 2024–2026.
Fiscal Year 2025
-
Record 2025 sales and EPS exceeded guidance, driven by strong growth in immunology and neuroscience. 2026 outlook projects 9.5% revenue growth, robust free cash flow, and continued pipeline advancement, despite ongoing Humira erosion and pricing headwinds.
-
Management emphasized a strategy of smaller, targeted deals to drive long-term growth, with robust R&D investment and margin expansion projected through 2029. Skyrizi and Rinvoq continue to lead in IBD and dermatology, while neuroscience and novel therapies like brotosilicin are poised for significant growth.
-
Panelists highlighted rising vaccine hesitancy, the enduring trust in healthcare professionals, and the importance of local voices in building confidence. U.S. pediatric vaccine access is robust, while global equity relies on creative partnerships. Advances in immunology, AI, and surveillance are shaping the future of vaccine innovation and preparedness.
-
Adjusted EPS and revenues exceeded expectations, driven by strong growth in immunology and neuroscience. 2025 guidance was raised, with robust pipeline progress and increased R&D investment, despite ongoing HUMIRA erosion and aesthetics market softness.
-
Management highlighted active policy engagement, robust growth in immunology, and strong new product launches. Strategic investments in manufacturing, neuroscience, and early-stage assets support long-term growth, while stable pricing and market access are expected through 2026.
-
Second quarter results exceeded expectations with strong growth in immunology and neuroscience, leading to raised full-year revenue and EPS guidance. Robust performance from SKYRIZI and RINVOQ, pipeline advancements, and strategic business development support a positive long-term outlook.
-
Productive policy engagement and robust financial performance support a strong growth outlook, with immunology, neuroscience, and oncology franchises driving momentum. Early-stage business development and pipeline innovation, especially in obesity and aesthetics, position the company for long-term expansion.
-
Management is proactively addressing policy risks, maintaining strong commercial and supply chain strategies, and expanding its pipeline through targeted M&A. The company is entering the obesity market with a differentiated asset and expects continued growth in immunology, supported by product innovation and market expansion.
-
Shareholders reviewed strong 2024 financial results, robust pipeline progress, and ongoing R&D investments. Key governance proposals to eliminate supermajority voting failed to pass, while dividends continued to grow. Strategic acquisitions and U.S. manufacturing investments were highlighted.
-
First-quarter results surpassed expectations with strong growth in immunology, neuroscience, and oncology, while aesthetics faced macro headwinds. Full-year guidance was raised for key products and overall EPS, supported by robust pipeline progress and strategic investments.
-
Leaders outlined a strategy focused on five growth platforms, with Skyrizi and Rinvoq driving immunology gains and a robust neuroscience and oncology pipeline. R&D investment is rising, highlighted by a new obesity program and multiple late-stage assets, supporting high single-digit growth through the decade.
-
Management highlighted robust growth through the decade, driven by a diverse late-stage pipeline in immunology, neuroscience, oncology, and eye care. Recent acquisitions and new indications are expected to add significant value, while margin expansion and underappreciated assets in migraine and oncology offer further upside.
-
Management projects robust growth through 2029, driven by immunology, oncology, and neuroscience, with Skyrizi and Rinvoq leading market share gains. Early-stage pipeline investments and innovation in aesthetics and neuroscience support long-term growth, despite near-term challenges in legacy products and aesthetics.
Fiscal Year 2024
-
Full-year adjusted EPS and revenues exceeded guidance, driven by strong growth in ex-Humira assets, especially Skyrizi and Rinvoq. 2025 guidance calls for robust operational growth despite Medicare Part D headwinds, with continued pipeline expansion and prudent capital allocation.
-
Ex-Humira business delivered strong growth in 2024, led by Skyrizi and Rinvoq, with robust momentum expected into 2025 despite ongoing Humira erosion. Pipeline progress in neuroscience and oncology, plus innovation in aesthetics, support long-term growth across key therapeutic areas.
-
Q3 delivered strong revenue and EPS growth, driven by Skyrizi and Rinvoq, offsetting Humira declines. Guidance for 2024 was raised, with robust performance across immunology, oncology, and neuroscience, and continued investment in pipeline innovation.
-
Q2 2024 saw strong operational sales growth, led by immunology and oncology, with ex-HUMIRA assets outperforming expectations. Full-year guidance was raised for both revenue and EPS, while aesthetics guidance was moderated due to market headwinds, but long-term growth outlook remains robust.
-
Ex-Humira platforms now generate over 80% of revenue, with strong growth expected above industry average in 2025 and high single-digit CAGR through the decade. Skyrizi and Rinvoq outperform, aided by trials and new indications. Neuroscience, oncology, and aesthetics pipelines are boosted by acquisitions and innovation. IRA and Part D impacts are managed.